||Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 556 active entries
181, avenue Jean Jaures
Phone: +33 (0)4 37 65 41 00
Fax: +33 (0)4 37 65 41 01
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
genOway is dedicated to the development of tailor-made genetically modified rat and mouse models of the highest reliability. Based on innovative proprietary technologies, genOway proposes time saving and cost effective strategies for in vivo drug development programs. These strategies allow the development of tailor-made “evolving” mouse models enabling the different questions which arise to be addressed with a single model: target validation, drug screening, drug efficacy and safety testing. Moreover, our license policy allows our partners to have a free use of the model developed for target validation and drug discovery purposes.
Focusing its effort on the mouse and rat, genOway has developed a complete range of innovative technological solutions to create better models. genOway's expertise combine technologies classically used in transgenesis (knock-out, knock-in, knock-down, conditional and inducible systems) and several cutting-edge proprietary technologies aiming at enhancing the efficiency and security of transgenesis projects: Safe DNA TransgenesisTM, Safe RNAi Transgenesis TM, Safe Large DNA Transgenesis TM, Safe Knock-out TM, Quick Knock-in TM and rat cloning.
The company has established business relationships with renowned academic research centres, major biotech companies and leading pharmaceuticals companies. Operating in 25 countries in Europe, North America and Asia, genOway is, with respect to staff and clients, the largest company in its field in Europe.
Last update of this entry: August 17, 2015